Medac
| medac
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | 1970 |
| Seat | Wedel, Germany |
| management | Jörg Hans, Lasse Lehnert, Heiner Will |
| Number of employees | over 1800 (2020) |
| sales | 386.3 million euros (2018/2019) |
| Branch | pharmacy |
| Website | www.medac.de |
The Medac Society of Clinical Spezialpräparate mbH is a German pharmaceutical company based in Wedel and Tornesch and is 100% privately owned.
Medac focuses on therapeutics for the treatment of oncological , urological and autoimmune diseases and their side effects. In addition, Medac produces therapeutics for fibrinolysis as well as diagnostics in the field of infection diagnostics and oncological diagnostics. Medac owns shares in two subsidiaries for the production of highly effective, sterile drugs such as cytostatics - Oncotec GmbH (50% share) in Dessau and oncomed as (90% share) in Brno , Czech Republic . In addition to generic products , Medac has also developed its own products that mainly cover therapeutic niches.
In addition to the therapeutic Medac also distributes human in vitro - diagnostics . The portfolio includes more than 40 infection diagnostics on a serological basis for bacterial and viral infections ( antibody detection ) and numerous direct detection of bacteria , fungi and viruses using PCR technology ( polymerase chain reaction ). In addition, Medac offers a wide range of reagents for tissue differentiation from tumor samples .
history
In April 1970, the medac Society for Special Clinical Preparations was founded in Hamburg by Wilfried Mohr, Claus-Olaf Welding, Werner Mai and Ernst Voss. The aim was the production of coagulation preparations and the production of fibrinolytics . Diagnostic products (antibodies) were already being marketed at this time. A short time later, Medac concentrated on the indication area of oncology and marketed the preparation Mitomycin C.
Today more than 50 oncological active ingredients are offered in different dosage forms for the treatment of numerous types of cancer. At the end of the 1980s a new area of indication emerged - the treatment of autoimmune diseases. Today medac is one of the leading suppliers of methotrexate , a folic acid antagonist for the treatment of rheumatoid arthritis in numerous doses and easily administered form .
Between 1997 and 2005 Schering AG held 25% of the company shares.
Individual evidence
- ↑ a b Information on company website
- ↑ Bundesanzeiger annual financial statements, accessed on May 10, 2020
- ↑ 40 years of medac - dynamic growth and social responsibility ( memento of the original from July 2, 2011 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. at wedel.de, accessed on November 27, 2011
- ↑ Approval number: Gliolan (EU / 1/07/413 / 001-003)
- ↑ Approval number: Mitomycin 2 (394.00.00) and Mitomycin medac (394.01.00)
- ↑ 40 years of medac - The growth continues. In: Deutsche Apotheker Zeitung of February 17, 2011, p. 125.
